Additional file 1: of Do men regret prostate biopsy: Results from the PiCTure study

The PiCTure Study – Prostate Investigations in Ireland. This is a pdf version of the questionnaire used in the Republic of Ireland. (PDF 1351 kb

Distribution of the primary study cohort (<i>n</i> = 10,139) by age, PSA at presentation, biopsy grade, and clinical stage.

<p>Distribution of the primary study cohort (<i>n</i> = 10,139) by age, PSA at presentation, biopsy grade, and clinical stage.</p

Calibration plots of the risk groups.

<p>(A) Calibration curves for prostate-cancer-specific survival using the new risk stratification system applied to the testing set (<i>n</i> = 4,113). (B) Model calibration curves for prostate-cancer-specific survival using the NICE risk stratification system applied to the testing set.</p

Survival stratified by risk group in the training set.

<p>(A) New risk stratification system applied to training set. (B) NICE risk stratification system applied to training set. Kaplan-Meier curves for prostate-cancer-specific survival and 95% confidence intervals (shaded areas) are shown for each risk group (<i>n</i> = 6,026).</p

Survival stratified by risk group in the testing set.

<p>(A) New risk stratification system applied to testing set. (B) NICE risk stratification system applied to testing set. Kaplan-Meier curves for prostate-cancer-specific survival and 95% confidence intervals (shaded areas) are shown for each risk group (<i>n</i> = 4,113).</p

Log-rank pair-wise comparison of new risk groups’ association with prostate-cancer-specific mortality in the testing set (<i>n</i> = 4,113).

<p>Log-rank pair-wise comparison of new risk groups’ association with prostate-cancer-specific mortality in the testing set (<i>n</i> = 4,113).</p

Cumulative incidence curves applied in the testing set to assess the competing mortality risks in the new model.

<p>Cumulative incidence curves applied in the testing set to assess the competing mortality risks in the new model.</p

Log-rank pair-wise comparison of new risk groups’ association with prostate-cancer-specific mortality in the training set (<i>n</i> = 6,026).

<p>Log-rank pair-wise comparison of new risk groups’ association with prostate-cancer-specific mortality in the training set (<i>n</i> = 6,026).</p

Proposed new prostate cancer risk stratification system.

<p>Proposed new prostate cancer risk stratification system.</p

Competing-risks regression analysis of the new risk model in the testing set.

<p>Competing-risks regression analysis of the new risk model in the testing set.</p